Understanding and improving heart problems in Myotonic Dystrophy
The role of TGFβs and cFAPs in Cardiac Pathology from RNA Toxicity
This project aims to understand why people with Myotonic Dystrophy type 1 (DM1) develop heart problems and explore new ways to treat them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11080353 on NIH RePORTER |
What this research studies
Myotonic Dystrophy type 1 (DM1) is a genetic condition that often causes serious heart issues, including irregular heartbeats and sudden death. Currently, we don't fully understand how these heart problems develop, which makes treatment challenging. This research uses a special mouse model to learn more about the underlying causes of heart damage in DM1, particularly focusing on how toxic RNA affects heart tissue. We are also exploring if a treatment called antisense oligonucleotides (ASOs) can help reverse these heart issues, offering a potential new path for therapy.
Who could benefit from this research
Good fit: Patients with Myotonic Dystrophy type 1 who experience or are at risk for heart complications are the ultimate beneficiaries of this foundational research.
Not a fit: Patients without Myotonic Dystrophy type 1 or those whose conditions are unrelated to RNA toxicity in the heart would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that prevent or reverse the life-threatening heart complications in individuals with Myotonic Dystrophy type 1.
How similar studies have performed: This research builds on previous work that successfully used a mouse model to show the potential of ASOs to treat DM1 heart disease, marking a novel approach in this area.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Mahadevan, Mani Subramaniam — University of Virginia
- Study coordinator: Mahadevan, Mani Subramaniam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.